KLRS PRESS-RELEASE SEC Filing Analysis

Latest settled — T+5d ⚠ clustered

KLRS ▼ -1.04% at T+5d

NEUTRAL call ✗ call lost -1.04% · α vs SPY -1.12% · entry $4.79 → $4.74

Next anchor: T+20d due 3d ago

Currently $4.33 · -9.60% from $4.79 entry

Entry anchored
May 11, 03:58 PM ET
via Databento tick

T+1d

+0.84%

call +0.84% · α +0.26%

$4.83

settled 4w ago

T+5d

-1.04%

call -1.04% · α -1.12%

$4.74

settled 25d ago

T+20d

—

call — · α —

—

due 3d ago

T+60d

—

call — · α —

—

in 8w

Price Chart

Loading chart...

Executive Summary

Kalaris Therapeutics reported Q1 2026 net loss per share of $(0.46), beating consensus of $(0.52) by 11.5%. The company continues to advance its lead candidate TH103 in a Phase 1b/2 study for neovascular AMD, with preliminary data expected in 1H 2027. Cash and equivalents stood at $104.9M, expected to fund operations into Q4 2027.

Actionable Insight

The EPS beat and cash runway into Q4 2027 provide near-term stability, but the stock's movement will depend on clinical data readouts in 1H 2027. Monitor for patient enrollment updates and any financing announcements, as the current cash burn rate may necessitate future capital raises.

Key Facts

Net loss per share $(0.46) vs consensus $(0.52) (11.5% beat)
Net loss of $10.9M in Q1 2026 vs $10.2M in Q1 2025
Cash, cash equivalents and marketable securities of $104.9M as of March 31, 2026
Phase 1b/2 trial of TH103 screening patients; preliminary data expected 1H 2027
R&D expenses increased to $7.6M from $6.0M year-over-year

Financial Impact

EPS beat of $0.06 per share vs consensus; cash burn rate ~$10.9M/quarter

epscashr&d spend

Risk Factors

Clinical trial failure or delays in TH103 development
Cash burn may require dilutive financing before data readout
No approved products or revenue

Market Snapshot

Exchange

Nasdaq

Sector

Biological Products, (No Diagnostic Substances)

Analyst Consensus

83% bullish (12 analysts)

Documents Analyzed

This report is based on 1 press release from GlobeNewswire.

Document	Accession Number
PRESS-RELEASE Data (Synthetic)	press-3292781

9 reports for KLRS

T+1T+5T+20T+60

67% Hit rate 2 of 3 directional calls best @ T+20▲ +18.73%Apr 14, 2026

Filters

Reports for KLRS — sortable, filterable
	Type				Now
Jun 11, 2026 2d ago	Institutional Cluster NEUTRAL ★ 3/10	$4.16 awaiting T+5	awaiting T+5	—	$4.33 (+4.09%)
May 12, 2026 4w ago	8-K NEUTRAL ★ 4/10	$4.79 $4.74	▼ −1.04%	▼ −1.12%	$4.33 (−9.60%)
May 12, 2026 4w ago	Press Release NEUTRAL ★ 4/10	$4.79 $4.74	▼ −1.04%	▼ −1.12%	$4.33 (−9.60%)
Apr 24, 2026 7w ago	DEFA14A NEUTRAL ★ 3/10	$6.02 $5.53	▼ −8.14%	▼ −8.54%	$4.33 (−28.07%)
Apr 14, 2026 8w ago	EFFECT BEARISH ★ 7/10	$5.82 $6.28	▼ −7.90%	▼ −6.51%	$4.33 (+25.60%)
Apr 10, 2026 9w ago	8-K NEUTRAL ★ 3/10	$6.31 $6.60	▲ +4.60%	▲ +1.30%	$4.33 (−31.38%)
Apr 3, 2026 10w ago	S-3 BEARISH ★ 6/10	$6.27 $6.31	▼ −0.64%	▲ +3.50%	$4.33 (+30.94%)
Apr 3, 2026 10w ago	S-3 NEUTRAL ★ 3/10	$6.27 $6.31	▲ +0.64%	▼ −3.50%	$4.33 (−30.94%)
Mar 17, 2026 12w ago	Press Release BULLISH ★ 7/10	$8.52 $6.20	▼ −27.23%	▼ −24.58%	$4.33 (−49.18%)

US Market Status

Market Closed — Opens Mon (49h 33m)

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access